Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 124Myelodysplastic Syndromes 119Precursor Cell Lymphoblastic Leukemia-Lymphoma 106Leukemia 85Hodgkin Disease 80Leukemia, Lymphocytic, Chronic, B-Cell 77Lymphoma 75Multiple Myeloma 74Lymphoma, Non-Hodgkin 74Myeloproliferative Disorders 57Graft vs Host Disease 55Lymphoma, Follicular 53Lymphoma, Mantle-Cell 49Lymphoma, Large B-Cell, Diffuse 49Leukemia, Myeloid, Accelerated Phase 49Leukemia, Myelomonocytic, Chronic 48Leukemia, Myelogenous, Chronic, BCR-ABL Positive 47Congenital Abnormalities 47Hematologic Neoplasms 45Leukemia, Myeloid, Chronic-Phase 44Lymphoma, B-Cell, Marginal Zone 43Primary Myelofibrosis 41Burkitt Lymphoma 41Blast Crisis 38Neoplasms, Plasma Cell 37Lymphoma, Large-Cell, Immunoblastic 33Waldenstrom Macroglobulinemia 25Myelodysplastic-Myeloproliferative Diseases 25Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 25Anemia, Refractory, with Excess of Blasts 24

Interventions

fludarabine phosphate 4Whole-Body Irradiation 4Cyclophosphamide 3Blood Specimen Collection 3Antilymphocyte Serum 3Alemtuzumab 3plerixafor 2Thiotepa 2Therapeutics 2Melphalan 2Cyclosporins 2Cyclosporine 2Busulfan 2thymoglobulin 1fosphenytoin 1fludarabine 1Voriconazole 1Vaccination 1Tacrolimus 1Photopheresis 1Phlebotomy 1Phenytoin 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Injections 1Holistic Health 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Exercise 1Clinical Trials, Phase I as Topic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Immunologic Deficiency Syndromes × Tacrolimus × Clear all
NCT02274662 2025-01-16

Expanded Access Protocol Thymus Transplantation

Sumitomo Pharma Switzerland GmbH

Phase 4 Completed
11 enrolled 10 charts

Thymic aplasia, Immunologic Deficiency Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡